Glaukos Corporation
GKOS
Rangering i aksjer
#1965
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Aksjekurs
$177.09
Sist synkronisert: 2026-10-21
Markedsverdi
$10.45B
Endring (1 dag)
1.76%
Endring (1 år)
131.10%
Land
US
Handel Glaukos Corporation (GKOS)
Kategori
Healthcare
Aksjeprishistorikk for Glaukos Corporation (GKOS)
Høyeste sluttskurs: $166.80 den 2026-10-01
Laveste sluttskurs: $29.05 den 2015-06-01
Laveste sluttskurs: $29.05 den 2015-06-01
Aksjeprishistorikk for Glaukos Corporation fra 2015 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 16.37% |
| 2025 | -22.38% |
| 2024 | 97.91% |
| 2023 | 64.84% |
| 2022 | 1.09% |
| 2021 | -38.87% |
| 2020 | 24.29% |
| 2019 | -5.51% |
| 2018 | 133.10% |
| 2017 | -22.73% |
| 2016 | 38.93% |
| 2015 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $100.56 | -21.41% |
US
|
|
| $93.07 | -2.95% |
IE
|
|
| $297.13 | -23.49% |
US
|
|
| $44.47 | -57.18% |
US
|
|
| $46.87 | -18.19% |
DE
|
